Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS).
Guselkumab, a fully human interleukin-23 antibody, is approved for systemic treatment of patients with moderate-to-severe plaque psoriasis. To compare efficacy and safety of guselkumab with fumaric acid esters (FAE) in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis. Eligible patients were randomised to this multicentre, randomised, open-label, assessor-blinded, active comparator-controlled phase 3b study to receive 100 mg guselkumab by subcutaneous injection or oral FAE according to local label guidelines. Through week 24, 56/60 patients completed guselkumab treatment and 36/59 patients completed FAE treatment. The primary endpoint (proportion of patients with ≥90% improvement from their baseline Psoriasis Area and Severity Index; PASI 90 response) was achieved by significantly more patients receiving guselkumab compared to FAE (81.7% vs. 13.6%, p<0.001) at week 24. Analysis of the major secondary endpoints confirmed a statistically significant difference between the treatments with regards to PASI 75 response (90.0% vs. 27.1%, p<0.001) and the Dermatology Life Quality Index (DLQI) response of 0/1 (no effect at all on patient's life; 61.7% vs. 16.9%, p<0.001). More patients in the guselkumab group achieved completely clear skin (PASI 100 response) compared with the FAE group (31.7 % vs. 3.4%; p<0.001). The incidence of adverse events (AE) was lower with guselkumab than with FAE (73.3% vs. 98.3%). Overall, 27.6% of FAE patients discontinued due to an AE compared with none receiving guselkumab. No new safety findings were observed for guselkumab. Guselkumab demonstrated superiority over FAE in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis through 24 weeks.